Skip to content

TransMedics Group, Inc. TMDX Free cash flow yield

Free cash flow yield at other companies

LivaNova logo
LivaNovaLIVN
4.6%-2.2pp
ICU Medical logo
ICU MedicalICUI
2.9%-1.0pp
Edwards Lifesciences logo
Edwards LifesciencesEW
2.4%
United Therapeutics logo
United TherapeuticsUTHR
3.9%-4.2pp
OSI Systems logo
OSI SystemsOSIS
1.7%+0.4pp

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Calculated from TransMedics Group, Inc.’s reported figures.

Based on trailing twelve months.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s free cash flow yield?
TransMedics Group, Inc. (TMDX) reported free cash flow yield of 4.4% in Q1 2026.
What is the long-term trend for TransMedics Group, Inc.'s free cash flow yield?
Over 4 years (2020 to 2025), TransMedics Group, Inc.'s free cash flow yield has grown at a -12.8% compound annual growth rate (CAGR), from -5.6% to 3.2%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.